SERUM NEURON-SPECIFIC ENOLASE: A MARKER FOR DISEASE EXTENT AND RESPONSE TO THERAPY OF SMALL-CELL LUNG CANCER

DesmondN Carney, DanielC Ihde, MartinH Cohen, PaulJ Marangos, PaulA Bunn, JohnD Minna, AdiF Gazdar

Research output: Contribution to journalArticle

293 Citations (Scopus)

Abstract

Serum neuron-specific enolase (NSE) levels in 94 newly diagnosed untreated patients with small-cell lung cancer (SCLC) were compared with those in 30 adult controls. 38 of the SCLC patients had limited disease and 56 had extensive disease. Serum NSE was raised (>12·0 ng/ml) in 69% of all patients (mean 52·35±11·56, range 4·1-850 ng/ml); it was raised in 15/38 (39%) of patients with limited stage disease and in 49/56 (87%) of those with extensive stage disease. Extensive stage patients had a significantly higher mean NSE level (59 ng/ml) than did limited stage patients (13·8 ng/ml). Serum NSE was raised in 34/41(84%) of patients with metastases at 1 or 2 sites and in all 15 patients with metastases at 3 or more sites. Serial measurements in 23 patients receiving combination chemotherapy showed an excellent correlation between serum NSE and clinical response. Continuous cell-lines of SCLC, established from 10 of the patients in this study, all expressed high levels of NSE. These studies indicate that serum NSE may be a useful marker for staging and for monitoring response to therapy in patients with SCLC.

Original languageEnglish (US)
Pages (from-to)583-585
Number of pages3
JournalThe Lancet
Volume319
Issue number8272
DOIs
StatePublished - Mar 13 1982

Fingerprint

Phosphopyruvate Hydratase
Small Cell Lung Carcinoma
Serum
Therapeutics
Neoplasm Metastasis
Combination Drug Therapy
Cell Line

ASJC Scopus subject areas

  • Medicine(all)

Cite this

SERUM NEURON-SPECIFIC ENOLASE : A MARKER FOR DISEASE EXTENT AND RESPONSE TO THERAPY OF SMALL-CELL LUNG CANCER. / Carney, DesmondN; Ihde, DanielC; Cohen, MartinH; Marangos, PaulJ; Bunn, PaulA; Minna, JohnD; Gazdar, AdiF.

In: The Lancet, Vol. 319, No. 8272, 13.03.1982, p. 583-585.

Research output: Contribution to journalArticle

Carney, DesmondN ; Ihde, DanielC ; Cohen, MartinH ; Marangos, PaulJ ; Bunn, PaulA ; Minna, JohnD ; Gazdar, AdiF. / SERUM NEURON-SPECIFIC ENOLASE : A MARKER FOR DISEASE EXTENT AND RESPONSE TO THERAPY OF SMALL-CELL LUNG CANCER. In: The Lancet. 1982 ; Vol. 319, No. 8272. pp. 583-585.
@article{210dc58951f64880acc915b113e4d2e5,
title = "SERUM NEURON-SPECIFIC ENOLASE: A MARKER FOR DISEASE EXTENT AND RESPONSE TO THERAPY OF SMALL-CELL LUNG CANCER",
abstract = "Serum neuron-specific enolase (NSE) levels in 94 newly diagnosed untreated patients with small-cell lung cancer (SCLC) were compared with those in 30 adult controls. 38 of the SCLC patients had limited disease and 56 had extensive disease. Serum NSE was raised (>12·0 ng/ml) in 69{\%} of all patients (mean 52·35±11·56, range 4·1-850 ng/ml); it was raised in 15/38 (39{\%}) of patients with limited stage disease and in 49/56 (87{\%}) of those with extensive stage disease. Extensive stage patients had a significantly higher mean NSE level (59 ng/ml) than did limited stage patients (13·8 ng/ml). Serum NSE was raised in 34/41(84{\%}) of patients with metastases at 1 or 2 sites and in all 15 patients with metastases at 3 or more sites. Serial measurements in 23 patients receiving combination chemotherapy showed an excellent correlation between serum NSE and clinical response. Continuous cell-lines of SCLC, established from 10 of the patients in this study, all expressed high levels of NSE. These studies indicate that serum NSE may be a useful marker for staging and for monitoring response to therapy in patients with SCLC.",
author = "DesmondN Carney and DanielC Ihde and MartinH Cohen and PaulJ Marangos and PaulA Bunn and JohnD Minna and AdiF Gazdar",
year = "1982",
month = "3",
day = "13",
doi = "10.1016/S0140-6736(82)91748-2",
language = "English (US)",
volume = "319",
pages = "583--585",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Elsevier Limited",
number = "8272",

}

TY - JOUR

T1 - SERUM NEURON-SPECIFIC ENOLASE

T2 - A MARKER FOR DISEASE EXTENT AND RESPONSE TO THERAPY OF SMALL-CELL LUNG CANCER

AU - Carney, DesmondN

AU - Ihde, DanielC

AU - Cohen, MartinH

AU - Marangos, PaulJ

AU - Bunn, PaulA

AU - Minna, JohnD

AU - Gazdar, AdiF

PY - 1982/3/13

Y1 - 1982/3/13

N2 - Serum neuron-specific enolase (NSE) levels in 94 newly diagnosed untreated patients with small-cell lung cancer (SCLC) were compared with those in 30 adult controls. 38 of the SCLC patients had limited disease and 56 had extensive disease. Serum NSE was raised (>12·0 ng/ml) in 69% of all patients (mean 52·35±11·56, range 4·1-850 ng/ml); it was raised in 15/38 (39%) of patients with limited stage disease and in 49/56 (87%) of those with extensive stage disease. Extensive stage patients had a significantly higher mean NSE level (59 ng/ml) than did limited stage patients (13·8 ng/ml). Serum NSE was raised in 34/41(84%) of patients with metastases at 1 or 2 sites and in all 15 patients with metastases at 3 or more sites. Serial measurements in 23 patients receiving combination chemotherapy showed an excellent correlation between serum NSE and clinical response. Continuous cell-lines of SCLC, established from 10 of the patients in this study, all expressed high levels of NSE. These studies indicate that serum NSE may be a useful marker for staging and for monitoring response to therapy in patients with SCLC.

AB - Serum neuron-specific enolase (NSE) levels in 94 newly diagnosed untreated patients with small-cell lung cancer (SCLC) were compared with those in 30 adult controls. 38 of the SCLC patients had limited disease and 56 had extensive disease. Serum NSE was raised (>12·0 ng/ml) in 69% of all patients (mean 52·35±11·56, range 4·1-850 ng/ml); it was raised in 15/38 (39%) of patients with limited stage disease and in 49/56 (87%) of those with extensive stage disease. Extensive stage patients had a significantly higher mean NSE level (59 ng/ml) than did limited stage patients (13·8 ng/ml). Serum NSE was raised in 34/41(84%) of patients with metastases at 1 or 2 sites and in all 15 patients with metastases at 3 or more sites. Serial measurements in 23 patients receiving combination chemotherapy showed an excellent correlation between serum NSE and clinical response. Continuous cell-lines of SCLC, established from 10 of the patients in this study, all expressed high levels of NSE. These studies indicate that serum NSE may be a useful marker for staging and for monitoring response to therapy in patients with SCLC.

UR - http://www.scopus.com/inward/record.url?scp=0020065737&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020065737&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(82)91748-2

DO - 10.1016/S0140-6736(82)91748-2

M3 - Article

C2 - 6121182

AN - SCOPUS:0020065737

VL - 319

SP - 583

EP - 585

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 8272

ER -